Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Allist Pharmaceuticals, Inc.
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05288205CT.gov Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation | — | Recruiting | — | — | — |
NCT04121286CT.gov A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China | — | Completed | — | — | — |
NCT04045496CT.gov A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Ductal Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Jab 3312 (this asset) | Allist Pharmaceuticals, Inc. | P1/2 | B · 57 |
| Daraxonrasib | Revolution Medicines, Inc. | P3 | BB |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | OHSU Knight Cancer Institute | P2 | BB |
| Rmc-6236 | Tango Therapeutics, Inc. | P3 | BB |
| S-1 | Genentech, Inc. | P2 | BB |
| (R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone | Corcept Therapeutics | P3 | BB |
| Ivospemin | Panbela Therapeutics, Inc. | P2/3 | BB |
| Oxaliplatin | Jonsson Comprehensive Cancer Center | P4 | BB |
| Metformin | British Columbia Cancer Agency | P2 | BB |
+42 more in the Pancreatic Ductal Adenocarcinoma cohort
Other indications for Jab 3312
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | B · 58 |
| Colorectal Cancer | — | P1/2 | CCC · 52 |
| Esophageal Squamous Cell Carcinoma | — | P1 | CC · 46 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- DaraxonrasibRevolution Medicines, Inc.BB
- Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, DimerOHSU Knight Cancer InstituteBB
- Rmc-6236Tango Therapeutics, Inc.BB
- S-1Genentech, Inc.BB
- (R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)MethanoneCorcept TherapeuticsBB
Citation
Floatz Terminal. Jab 3312 in Pancreatic Ductal Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/jab-3312-pancreatic-ductal-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →